(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 94.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 21.94%.
Agios Pharmaceuticals's revenue in 2026 is $54,028,000.On average, 12 Wall Street analysts forecast AGIO's revenue for 2026 to be $5,561,334,598, with the lowest AGIO revenue forecast at $3,847,162,014, and the highest AGIO revenue forecast at $7,167,580,401. On average, 12 Wall Street analysts forecast AGIO's revenue for 2027 to be $14,883,583,531, with the lowest AGIO revenue forecast at $9,141,550,675, and the highest AGIO revenue forecast at $20,623,858,622.
In 2028, AGIO is forecast to generate $22,976,334,328 in revenue, with the lowest revenue forecast at $14,670,893,947 and the highest revenue forecast at $29,333,584,990.